Effectiveness and safety of ATM-ATI in special populations
Pfizer Research & Development is a key contributor to scientific breakthroughs, with more than 414 million patients reached globally with our medicines and vaccines in 2024
This competitive program aims to evaluate the pharmacokinetics-pharmacodynamics (PK-PD), effectiveness, and safety of Aztreonam-Avibactam (ATM-AVI)1-2 in special adult populations. The study will focus on critically ill patients with suspected or confirmed carbapenemresistant Enterobacterales (CRE) infections, including Metallo-βlactamase (MBL)-producing CRE in China. Special populations include patients undergoing continuous renal replacement therapy (CRRT), extracorporeal membrane oxygenation (ECMO), chronic renal failure (CRF), sepsis, and end-stage renal disease (ESRD).
Potential applicants are requested to submit research proposals to study PK-PD, effectiveness, and safety of ATM-AVI for CRE (including MBL-CRE) infections in special adults population.
• PK-PD and target attainment in patients with CRF, ESRD including on different modalities of CRRT.
• PK-PD and target attainment in patients on patients with sepsis, immunosuppression, including on ECMO.
• Effectiveness and safety of ATM-AVI in special adults populations including those on CRRT, CRF, ESRD, sepsis, immunosuppression and ECMO.
Expected Approximate Monetary Range of Grant Applications:
• Individual projects requesting up to $68,800 will be considered. The estimated total available budget related to this RFP is $275,000.
• Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.